Home/ Stocks/ DCTH

Delcath Systems Inc

DCTH XNAS

$11.48 +0.24 (+2.14%) ▲ 15-min delayed

Open

$11.36

High

$11.49

Low

$11.03

Volume

569.7K

Market Cap

$396.31M

About Delcath Systems Inc

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Sector: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS Employees: 156 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$24.99M	$-1,070,000	$-0.03
FY 2025	$85.23M	$2.70M	$0.08
Q3 2025	$20.56M	$830.0K	$0.02
Q2 2025	$24.16M	$2.70M	$0.08

Earnings & Analyst Ratings

Next Earnings: Tue, Aug 4, 2026

Calendar →

Related Market News

No specific coverage for DCTH yet. Check out our latest market news or earnings calendar.

Get DCTH Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Delcath Systems Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.